What's Happening?
Atom Therapeutics, a biotechnology company focused on inflammatory and metabolic diseases, is set to present updates on its clinical trials at the BIO International Convention 2026 in San Diego. The company is advancing two lead drugs: Lingodlinurad (ABP-671),
a URAT1 inhibitor for chronic gout, and ABP-745, an anti-inflammatory drug for acute gout flares. Lingodlinurad has shown significant efficacy in reducing serum uric acid levels in Phase 2b trials, with Phase 3 trials underway in China and planned internationally. ABP-745 has demonstrated safety and tolerability in early trials, with a Phase 2 trial for acute gout expected to report data in August 2026. Additionally, ABP-745 is being tested for atherosclerotic cardiovascular disease, with promising results in inhibiting inflammatory processes.
Why It's Important?
The development of effective treatments for gout is crucial due to the limited options currently available for this painful condition. Atom Therapeutics' advancements could provide relief for patients suffering from chronic and acute gout, potentially improving quality of life and reducing healthcare costs associated with long-term management of the disease. The company's focus on inflammatory pathways also holds promise for broader applications in cardiovascular diseases, which are a leading cause of mortality worldwide. Successful trials could position Atom Therapeutics as a key player in the biotechnology sector, driving innovation and potentially attracting investment.
What's Next?
Atom Therapeutics plans to continue its clinical trials, with Phase 3 studies for Lingodlinurad set to expand internationally. The company is also preparing for Phase 2 trials of ABP-745 for additional heart-related conditions, including pericarditis and heart failure. The upcoming presentation at the BIO International Convention will provide an opportunity for Atom Therapeutics to engage with potential partners and investors, potentially accelerating the development and commercialization of its treatments.
